AQR Capital Management LLC Grows Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

AQR Capital Management LLC lifted its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 76.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,268,760 shares of the company's stock after acquiring an additional 986,132 shares during the period. AQR Capital Management LLC owned approximately 1.71% of Organogenesis worth $6,353,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ORGO. Los Angeles Capital Management LLC raised its position in Organogenesis by 45.9% during the first quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company's stock valued at $1,422,000 after purchasing an additional 157,575 shares in the last quarter. Denali Advisors LLC purchased a new stake in Organogenesis during the first quarter valued at about $129,000. Principal Financial Group Inc. bought a new position in shares of Organogenesis during the first quarter valued at about $100,000. BNP Paribas Financial Markets grew its stake in shares of Organogenesis by 573.9% during the first quarter. BNP Paribas Financial Markets now owns 123,386 shares of the company's stock valued at $350,000 after buying an additional 105,078 shares during the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Organogenesis by 102.8% during the first quarter. GSA Capital Partners LLP now owns 531,218 shares of the company's stock valued at $1,509,000 after buying an additional 269,315 shares during the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Trading Up 7.7 %

Shares of NASDAQ ORGO traded up $0.22 during trading hours on Friday, hitting $3.08. The company's stock had a trading volume of 231,133 shares, compared to its average volume of 867,288. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73. The stock has a market cap of $408.32 million, a price-to-earnings ratio of 76.27 and a beta of 1.62. Organogenesis Holdings Inc. has a 12 month low of $1.96 and a 12 month high of $4.70. The business has a 50-day simple moving average of $2.77 and a 200-day simple moving average of $2.74.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $130.23 million for the quarter, compared to the consensus estimate of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. On average, analysts anticipate that Organogenesis Holdings Inc. will post -0.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Lake Street Capital started coverage on Organogenesis in a research note on Friday, June 28th. They set a "buy" rating and a $5.00 price objective on the stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.